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Abstract
This chapter is dedicated to cytoreductive procedures and hyperthermic  
intraperitoneal chemotherapy (HIPEC) in the treatment of advanced ovarian 
cancer. Cytoreductive procedures and HIPEC constitute nowadays an important 
weapon in the surgical armamentarium used to treat ovarian cancer. Our service led 
by Dr. Moldovan Bogdan has an experience of 235 patients that underwent a HIPEC 
procedure, with an average of 33,5 cases/year which places us among some of the 
most experienced teams worldwide. We propose a chapter describing the indica-
tions and contraindications of such procedures, the surgical approach, followed by 
a description of our experience, including a review of our indications, the type of 
chemotherapeutic agents and a case example.
Keywords: cytoreductive surgery, HIPEC, carcinomatosis, hyperthermic 
intraperitoneal chemotherapy, cisplatin, doxorubicin
1. Introduction
Ovarian cancer ranks as the seventh most common cancer in women worldwide, 
as shown by a metanalysis of 125 articles published between 1925 and 2018 [1]. 
This frequency also comes with a non-neglectable mortality which in the same 
meta-analysis is estimated at 4,4% of all the cancer cases, in 2018. The mortality 
index is mostly due to the fact that the diagnosis is made when the disease is already 
advanced with two thirds of the mortality being attributed to advanced forms of 
serous carcinoma. Even with the current care recommendations which involve 
standard cytoreductive surgery and multiple lines of chemotherapy the confounded 
long-term survival for all disease stages is only 20–30% and is mostly due to peri-
toneal carcinomatosis [1–6]. As such we find that completing the cytoreductive 
surgery with hyperthermic intraperitoneal chemotherapy is the best way to ensure 
the best possible outcomes for ovarian cancer patients. A review of the current 
literature shows that it improves the 5-year survival to 24–60% compared to an 
average life expectancy of 12 to 25 months with standard chemotherapy [4, 7].
The aim of this chapter is to bring insight into our current surgical practice of 
performing extensive cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy.
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2. Historic perspective and rationale for HIPEC
Over time our view of peritoneal carcinomatosis evolved from considering it a 
terminal disease to considering it a form of locally advanced disease amenable to 
surgery which is sometimes with curative intent. The first to introduce the concept 
of cytoreductive surgery was Griffiths in 1975. His work shows a direct link between 
the radicality of the surgery and the survival of the patients [8, 9]. Five years later 
Spratt et al. show that hyperthermic intraperitoneal chemotherapy is feasible in 
peritoneal carcinomatosis [10, 11] and finally, in 1995 Sugarbaker et al. describe the 
technique of complete peritonectomy with an extraperitoneal approach, which in 
our opinion is the most suitable technique for most of the cases. He also described 
the combination of his technique with HIPEC [10].
If we look at the literature, we find articles clearly showing that the peritoneum 
in general and regions where scars exist – port sites for example are more prone 
to metastasis compared to solid organs and systemic chemotherapy is effective in 
about one third of the cases, with a complete response in only 15% of the cases [11]. 
Hence cytoreduction is extremely important to reduce tumor burden and HIPEC 
augments its efficacy by the lavage itself which, performed in a recent postopera-
tive setting helps flush the cells resulted from manipulating bulky lesions such as is 
often the case. It also helps by activating heat shock proteins due to the temperature 
which is around 42 degrees and gives the chemotherapeutic agent a chance to act 
locally by putting it in direct contact with the peritoneum.
3. HIPEC indications
The established concept of cytoreduction and HIPEC in peritoneal carcinomato-
sis is that they are to be performed in advanced stages of the disease, however more 
and more articles, starting with Sugarbaker and continuing with other high-volume 
surgical centers propose using HIPEC as a prophylactic measure not only in ovarian 
cancer but also in advanced appendiceal, colonic or gastric malignancies [11–19]. 
Keeping this in mind, it is our opinion that in the surgical management of ovarian 
cancer we will soon be able to classify HIPEC procedures into prophylactic – in 
stages up to II B and conventional – in stages III and IV. Because of the aggressive-
ness of the procedure, in each and every case we operate we struggle to achieve a 
complete cytoreduction, otherwise known as CC0 and in order to preoperatively 
assess in which patients this might be achieved we use staging scores such as the 
Fagotti score.
Initially, the Fagotti score [20] was described as a laparoscopic means of assess-
ing the feasibility of a HIPEC procedure, but because all surgical manipulation of 
the peritoneum decreases the chances to perform a radical surgery, we substitute the 
laparoscopic Fagotti score with an imaging score based on a good quality abdominal 
and pelvic contrasted, diffusion weighed magnetic resonance imaging (MRI). Besides 
avoiding unnecessary manipulation of the peritoneum, we consider it superior to 
laparoscopy because it allows us to assess the areas of the abdomen and pelvis which 
are difficult to evaluate surgically, especially in a patient that has had previous 
abdominal surgery. Similar to it is also the Bristow CT score, but in our opinion the 
Fagotti score based on a good quality MRI examination is better [21].
The Fagotti score contains 5 variables – omental cake, diaphragmatic carci-
nomatosis, mesenteric retraction, bowel/stomach infiltration and spleen/liver 
metastasis. If present, each variable receives 2 points. If the Fagotti score obtained 
on the MRI is less than 8 we go ahead and prepare the patient for HIPEC, while if 
the score is higher than 8 we prefer to perform a Pressurized Intraperitoneal Aerosol 
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Chemotherapy (PIPAC) session, continue chemotherapy and reassess the patient by 
the same MRI score 4–6 weeks after. We can perform 2–3 such PIPAC sessions in the 
hopes of achieving operability.
Besides the Fagotti score which in our opinion is the best tool for staging ovar-
ian peritoneal carcinomatosis and the Bristow score, there are several other scores 
which we only mention but not describe in detail as they are not used in case of 
ovarian cancer carcinomatosis – the Peritoneal Cancer Index (PCI) proposed in 
1996 by Sugarbaker and Jaquet [15, 16], the Gilly staging [15, 17] and the simplified 
PCI system proposed by Zoetmulder [18].
In conclusion to this subsection on staging scores we would like to talk about our 
standard preoperative workup in cases which are referred to our center as candi-
dates for cytoreductive surgery and HIPEC. This includes an MRI of the abdomen 
and pelvis with contrast and diffusion weighted imaging and a chest CT.
We prefer MRI because in our experience it correlates best with what we would 
find on an exploratory laparoscopy allowing us to obtain a more accurate Fagotti 
score. The chest CT allows us to define the intrathoracic involvement and plan for 
an eventual diaphragmatic resection. We place bilateral chest tubes at the end of 
the procedure and if needed the chest drain can also be connected to the HIPEC 
machine in order to have cytostatic agent circulating also in the pleural cavity.
Based on the imaging findings we can define not only the patients with better 
chances for having a complete resection but also those where there is a contraindica-
tion for HIPEC. The contraindications can be classified in absolute and relative.
Absolute contraindications are:
• inoperable invasion of the liver hilum;
• diffuse, inoperable liver metastases;
• diffuse small bowel lesions in which resection would mean leaving less than 
1 m of small bowel;
• unresectable retroperitoneal lymph node masses;
• inoperable distant metastasis.
Relative contraindications are:
• locally advanced multiple relapses, resistant to different chemotherapy 
regimens;
• progression under neoadjuvant therapy;
• bad performance status and comorbidities.
Pleural involvement which is common, is not a contraindication for performing 
HIPEC, but rather an indication to also perform hyperthermic intrathoracic chemo-
therapy (HITOC), eventually as staged procedures.
4. Timing of the cytoreductive and HIPEC procedures
Because of the variability of the moment when ovarian cancer is diagnosed 
there are several moments in the natural history of an ovarian cancer case when 
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cytoreductive procedures and HIPEC can be performed as can be seen in the analy-
sis performed by Helm et al. [14].
The first such moment and the one in which cytoreduction and HIPEC give the 
best chances of survival is when the diagnosis is made, if complete cytoreduction 
can be achieved [2]. In the moment of diagnosis, depending on the extent of the 
disease we can talk about prophylactic HIPEC or conventional HIPEC in later stages 
[19]. Prophylactic HIPEC in ovarian cancer refers to stages I and II in which we have 
a cytology sample which is positive for tumor cells, which suggests an increased 
risk for peritoneal relapse and a decision is made together with the patient and the 
oncologist to perform HIPEC with a preventive thinking in mind.
Another moment for HIPEC and cytoreduction is after neoadjuvant chemo-
therapy, because most ovarian cancers respond well to chemotherapy and become 
operable after a neoadjuvant treatment. The only disadvantage is that it might 
downsize the peritoneal implants, rather than really downstage the tumor and 
thus hide implants that otherwise would have been resected, increasing the risk for 
recurrence.
HIPEC can also be performed as a consolidation therapy after neoadjuvant 
chemotherapy, meaning that it is performed during a second look laparotomy when 
peritoneal biopsies reveal residual disease.
Another occasion on which these procedures might become useful in ovarian 
cancer is when a peritoneal relapse is diagnosed and surgery is performed usually 
after a new course of neoadjuvant chemotherapy which will also determine the 
chemotherapeutic agent to be used based on the response of the tumor.
Finally, the last situation in which we would perform HIPEC is as a last resort 
treatment – basically a salvage procedure.
5. Description of the technique for cytoreductive surgery
In ovarian cancer most of the authors recommend a selective peritonectomy 
technique and not a total peritonectomy, but in our hospital we prefer performing a 
total extraperitoneal (Sugarbaker) peritonectomy because we have more experience 
with it and we consider it more radical based on our results [22, 23]. An example of 
extraperitoneal peritonectomy can be seen in Figures 1 and 2.
Figure 1. 
Sugarbaker extraperitoneal peritonectomy.
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We start by detaching the peritoneum completely without opening it by entering 
a plane located between the peritoneum and the rectus sheath. We continue in this 
plane laterally until reaching the peritoneum, cranially until the Glisson’s capsule and 
inferiorly we resect the peritoneum covering the bladder with the uterus and the two 
adnexae, with or without the rectum. As patients usually come to us after a staging 
laparotomy performed elsewhere, we start by resecting the previous scars which 
are the most common sites of future relapses. We usually start below the umbilicus 
as this is the place where we can develop the correct plane at greater ease. Once the 
round ligament is cut at the level of the deep inguinal ring we can dissect easily later-
ally until reaching the retroperitoneum and exposing the iliac vessels and the ureters.
We then develop the plane cranially. Sometimes splenectomy is necessary if 
implants are seen on it or close to it, but it is not indicated as a rule in ovarian  
cancer.
Once the peritoneum is detached completely cranially and laterally, we enter 
the peritoneal cavity. A first resection specimen is constituted by the median 
scar, the umbilicus, the round ligament of the liver which is cut at the level of 
Rex’s recess, the falciform ligament and the urachal fold down to the bladder. 
The remaining peritoneum will be split into four quadrants. Completing the 
peritonectomy of the right upper quadrant is considered the most difficult as it 
consists of:
• resecting the diaphragmatic peritoneum, sometimes with a piece of 
diaphragm;
• dissection of the Glisson’s capsule, if affected, with the eventual metastases;
• cholecystectomy
• liver hilum lymph node dissection
• right colo-epiploic takedown with dissection of the posterior peritoneal sheath 
of the omental bursa
• resection the peritoneum of the Morison space
Figure 2. 
Sugarbaker extraperitoneal peritonectomy view once the peritoneal cavity is opened.
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• selective peritonectomy of the space between the caudate lobe, the inferior 
vena cava and the right diaphragmatic crux
In the left upper quadrant, the peritonectomy means:
• resecting the diaphragmatic peritoneum, sometimes with a piece of 
diaphragm;
• left colo-epiploic takedown
• dissection of the greater curvature
• resection of the peritoneum with or without the spleen
• mobilization of the left colonic flexure, sometimes requiring a colectomy
In the lower abdomen the peritonectomy includes:
• dissection of the peritoneum covering the urinary bladder
• dissection and section of the ovarian vessels
• dissection of the ureters in order to expose and ligate the uterine vessels safely
• sectioning the vagina below the cervix
• dissection of the peritoneum of the Douglas pouch when it is normal macro-
scopically or with the rectum if there are visible tumor implants
• appendicectomy
• sometimes colonic resections
• pelvic and paraaortic lymphadenectomy.
• sometimes a bladder resection or vascular resections might be necessary
In the central part of the abdomen the small intestine is examined carefully on 
both sides. Severely affected portions of the small bowel are resected carefully, 
keeping in mind in mind the risk for short bowel and taking away as little bowel 
as possible. Mesenteric implants are either resected or Argon beam coagulated. 
Atypical resections of the stomach can also be performed with the use of linear 
staplers.
Keeping in mind that the cytoreduction is usually followed by HIPEC we are 
faced with some delicate decisions regarding the anastomoses we perform. For 
small bowel we perform a 2-layer latero-lateral continuous suture without stoma. 
For colorectal anastomoses we perform a mechanical anastomosis using a circular 
stapler and protecting the anastomosis with a colostomy which we prefer to an 
ileostomy. And finally, there are cases where we do not perform an anastomosis 
but rather an end colostomy or ileostomy. These are mostly CC1 cases, posterior 
pelvic exenteration cases or total colectomy cases in fragile patients, even with a 
CC0 resection where an anastomosis would be too risky due to the status of the 
patient.
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6. Assessing the completeness of cytoreduction – the radicality score
It is considered the most important prognostic score, being estimated at the 
end of the cytoreductive stage. The penetrability of intraperitoneal chemotherapy 
is possible for lesions up to 2.5 mm. For most intraperitoneal neoplasms, complete 
CC0 cytoreduction is required, the CC1 score being considered acceptable only for 
peritoneal pseudomyxoma, a neoplasm with reduced aggressiveness. The radicality 
of resection classification is as follows: CC0 – no residual disease, CC1 – residual 
lesions smaller than 0,25 cm, CC2 – residual lesion between 0,25 and 2,5 cm and 
CC3 – residual lesions larger than 2,5 cm [18].
The impossibility of a radical surgery CC0-CC1 can determine the change of the 
operative strategy, either towards a palliative debulking surgery, or towards giving 
up any gesture of excision. In chemotherapy “naive” tumors, the maximum cytore-
duction with HIPEC followed by adjuvant CT is to be considered.
7. Description of the HIPEC procedure
For reasons related to the safety of handling cytostatic substances, most HIPEC 
teams in Europe, including our team use the “closed abdomen” technique in which 
the abdomen is closed permanently or only temporarily (the skin), with 4 drains 
inside, coupled to extracorporeal circulation device.
In short, the Rand Performer HT device that we use in our current activity, has 
the following components: 1) a heater or heat exchanger; 2) a pump system, which 
includes one or two peristaltic pumps; 3) a tank containing the infusion solution; 4) 
a circuit that distributes the drugs and heated fluid to the patient’s peritoneal cavity. 
In 1999 the Italian Biomedical Company (RanD Biotech SRL, Medolla, Italy) was 
the first to develop a device dedicated to HIPEC, used especially for the treatment by 
hyperthermic perfusion of the peritoneal cavity. The most important advantage of this 
device (Performer HT) is its portability and adaptability for various purposes, as it can 
also be used to infuse isolated anatomical regions or organs, such as the treatment of 
an isolated limb or the separate infusion of the liver or lung. The Performer HT device 
ensures a flow rate of 100–2000 ml/min and it has up to 8 temperature monitoring lines 
in various areas of the peritoneal cavity, which has the ability to measure temperatures 
between 28 °C and 46 °C. In our practice we use tubes with a diameter of 28 Fr, two 
for inlet (1 - subdiaphragmatic and 1 - in the pelvis) and two for the outlet (1 - sub-
diaphragmatic and 1 - in the pelvis). We also use two lines for monitoring the intra-
abdominal temperature mounted in the pelvis and in the supramesocolic space. In terms 
of the perfused solution, we use 4–6 liters of warm transport solution (2/3 Ringer, 1/3 
Voluven). Once an optimal infusion rate (> 800 ml/min) and an optimal intraperitoneal 
temperature around 42-43 °C is reached, the cytotoxic drugs are administered. We use 
Cisplatin (43 mg/L solution/m2) or Doxorubicin (15 mg/L solution) for carcinomatosis 
due to serous ovarian cancer. The duration of chemoperfusion is between 60 and 
90 minutes. At the end of the procedure, the abdomen is rinsed with 3 liters of saline 
and the drains are left in place.
As to the choice of the chemotherapeutic drug, it takes into account the sensitiv-
ity of the tumor to platinum salts, which can be seen preoperatively by the response 
of the tumor to the neoadjuvant chemotherapy. Platinum-sensitive patients will fol-
low the Cisplatin protocol, Platinum-resistant patients, the Doxorubuicin protocol.
• Cisplatin (43 mg/L solution/m2) - for Platinum CEO sensitive.
• Doxorubicin (15 mg/L solution) - for CEO resistant Platinum.
Ovarian Cancer - Updates in Tumour Biology and Therapeutics
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Other types of protocols using Taxol, Oxaliplatin, 5 Fluorouracil or Mitomycin 
C, etc. are also cited in the literature.
8. Our experience
In our experience we performed cytoreductive surgery and HIPEC on a number 
of 235 cases since we started performing these procedures in our hospital on the 5th 
of June 2013 which means an average of 33,5 cases/year. From a surgical point of 
view, critically speaking there were 2 stages: the initial experience 2013-December 
2014, dominated by surgical caution, fear of complications, selective peritonectomy 
by “open” approach, after intraperitoneal exploration and the second stage, starting 
from January 2015, with the introduction of the Sugarbaker-Deraco extraperitoneal 
total peritonectomy technique, marked by increased aggression, the association of 
multiorgan resections often with digestive anastomoses.
Of these patients there were 188 (80%) females and 47 (20%) males. The mean 
age of the patients was 60,92 ± 10,64 years. The mean hospital stay was 9,23 ± 3,66 
with a minimum of 4 days and a maximum of 32 days. In terms of overall survival, 
182 out of 203 patients (89,65%) survived at 1 year and 15 out of 75 patients (20%) 
survived at 5 years. The mean operating time for these cases was 7,21 ± 0,7 hours 
and the mean PCI was 14,5 ± 0,3.
Because of the number of patients and the variety of the pathology we preferred 
to give a visual representation of the type of pathology approached (Figure 3), the 
type of chemotherapeutic agent we used (Figure 4) and whether or not we did a 
stoma and what type of stoma we did (Figure 5). In terms of the radicality of resec-
tion you can see in Figure 6 the proportions of CC0, CC1 and CC2 resections.
Of particular importance in 2020, we had to reorganize our in-hospital protocols 
in order to ensure a COVID-free surgical department which allowed us to perform 
29 cytoreductive procedures followed by HIPEC since the pandemic was declared 
on March 11th 2020. We were able to do this by thoroughly screening admitted 
patients by aligning ourselves to the guidelines emitted by the major surgical and 
Figure 3. 
Types of pathologies approached by cytoreduction and HIPEC in our experience.
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oncological international societies. Initially our screening consisted in PCR tests 
from nasopharyngeal swab, rapid antibody test and chest CT and according to the 
guidelines we started only performing PCR from nasopharyngeal swab, leaving 
rapid antibody and antigen tests and chest CT scans only for patients in which we 
had a strong clinical suspicion of COVID and a negative PCR test [24].
Figure 4. 
Cytostatic agents used in our experience.
Figure 5. 
Use of stomas in our experience.
Ovarian Cancer - Updates in Tumour Biology and Therapeutics
10
In terms of multiorgan resections of note are cases of associations between 
posterior pelvic exenteration, right hemicolectomy and resection of liver metas-
tases, resection of ureter, bladder horn and uretero-vesical reimplantation, total 
colectomy with extended jejuno-ileal enterectomy, entero-enteral anastomosis and 
right iliac terminal ileostomy, association of posterior exenteration with regulated 
left hepatic lobectomy and radiofrequency thermoablation of liver metastasis.
Figure 7. 
Intraoperative pictures showing multiple organ resections in a patient with recurrent ovarian carcinoma.
Figure 6. 
Radicality of resection in our experience.
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As an example, we would like to present a case of ovarian carcinoma recurrence 
in a 51 years-old patient previously operated and treated by chemotherapy. The 
PCI was calculated to be 19 and we performed a CC0 resection with a Sugarbacker 
extraperitoneal approach associated with a Hartmann resection, multiple liver 
resections, diaphragmatic resection with phrenic reconstruction, appendicectomy, 
omentectomy, HIPEC - Doxorubicin 80 mg 60 minutes at 42 °C. Some intraopera-
tive pictures can be seen in Figure 7. The patient is still living at 3 years after the 
procedure and does not show signs of recurrence, despite the fact that she was 
considered untreatable by other centers before coming in our service.
9. Conclusion
Cytoreductive surgery and HIPEC now offer an alternative to ovarian cancer 
patients that were once considered inoperable and in high-volume centers the 
complications are minimal. This chapter provides insight into the technique 
of cytoreductive surgery and HIPEC and presents our experience with these 
techniques.
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